ERBB2 and colorectal carcinoma: Another phase I study (NCT04660929) is currently investigating the safety and tolerability of HER2-directed CAR macrophages (CarM) therapy, CT-0508, combined with pembrolizumab in HER2-positive tumors including CRC [97].